Medicine and Dentistry
Adverse Event
100%
Breast Cancer
100%
Postmenopause
100%
Aromatase Inhibitor
100%
Adjuvant Endocrine Therapy
100%
Tamoxifen
83%
Fracture
50%
Odds Ratio
33%
Cardiovascular System
33%
Cancer
33%
Recurrent Disease
16%
Linear Regression Analysis
16%
Monotherapy
16%
Endometrial Cancer
16%
Adjuvant
16%
Cerebrovascular Disease
16%
Phlebothrombosis
16%
Hormone Receptor
16%
Sequential Analysis
16%
Keyphrases
Postmenopausal Women
100%
Adverse Events
100%
Early Breast Cancer
100%
Aromatase Inhibitors
100%
Adjuvant Endocrine Therapy
100%
Bone Fracture
50%
Odds Ratio
33%
Secondary Malignancy
33%
Toxicity Profile
33%
Improved Outcomes
16%
Breast Cancer
16%
Cardiovascular Risk
16%
Cardiovascular Events
16%
Monotherapy
16%
Cerebrovascular Disease
16%
Treatment Discontinuation
16%
Endometrial Cancer
16%
Venous Thrombosis
16%
Weighted Linear Regression
16%
Hormone Receptor-positive Breast Cancer
16%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
100%
Breast Cancer
100%
Endocrine Therapy
100%
Aromatase Inhibitor
100%
Tamoxifen
83%
Fracture
50%
Monotherapy
16%
Adjuvant
16%
Recurrent Disease
16%
Cerebrovascular Disease
16%
Endometrium Cancer
16%
Vein Thrombosis
16%
Hormone Receptor
16%